Try our Advanced Search for more refined results

Loestrin 24 FE Antitrust Litigation

  1. September 02, 2020

    $184M Settlements OK'd In Loestrin Buyers' Antitrust Row

    A Rhode Island federal judge has given the final green light to deals totaling about $183.5 million to settle allegations that Lupin and a pair of Allergan units worked to sideline generic alternatives of the birth control drug Loestrin.

  2. April 21, 2020

    Loestrin Buyers' Attys Seek $43M From Antitrust Deal

    The legal team that helped direct buyers of birth control Loestrin snag a $120 million deal with drugmakers Warner Chilcott and Watson Pharmaceuticals over antitrust and fraud allegations is seeking just under $43 million of the pot to cover fees and expenses.

  3. January 06, 2020

    Allergan To Pay $300M To End Birth Control Antitrust Case

    Allergan said on Monday that it has agreed to pay several groups of Loestrin buyers a total of $300 million and will avoid a looming trial over claims that a pair of its subsidiaries delayed generic alternatives to the birth control drug.

  4. November 15, 2019

    Retailers Can Split Claims In Loestrin Antitrust Trial

    A group of retailers that bought the hormonal birth control pill Loestrin will be allowed to split their claims from the rest of the direct purchaser class in the upcoming trial over whether two pharmaceutical companies worked together to keep generic versions of the pill off the market.

  5. October 24, 2019

    Loestrin Buyers' $1M Lupin Deal Gets Initial Approval

    Lupin Pharmaceuticals Inc. and a group of end payors won preliminary approval of a $1 million settlement to end their portion of multidistrict litigation accusing the drugmaker and two other pharmaceutical companies of colluding to keep generic versions of the birth control drug Loestrin off the market.

  6. October 04, 2019

    Retailers Win Fight Over How To Carve Loestrin Antitrust Trial

    Retailers who bought the hormonal birth control pill Loestrin have won a contentious fight over how to slice up an approaching multidistrict litigation trial over whether two pharmaceutical companies worked together to keep generic versions of the pill off the market.

  7. September 23, 2019

    Loestrin Judge Assigns Antitrust Homework Before Hearing

    The Rhode Island federal judge handling Loestrin buyers' fraud and antitrust claims against drugmakers Warner Chilcott and Watson Pharmaceuticals directed both sides to answer questions related to the pharma companies' market power ahead of next week's potentially packed case hearing.

  8. August 26, 2019

    Loestrin Buyers Say Splitting Trial In 3 Would Cause Chaos

    Buyers of hormonal birth control pill Loestrin are urging a Rhode Island federal judge not to let another class of buyers split antitrust and fraud claims in the multidistrict litigation into three trials, saying that to do so would invite error and "trial chaos."

  9. August 12, 2019

    Pharmas Seek Separate Fraud, Antitrust Trials In Loestrin MDL

    Warner Chilcott and Watson Pharmaceuticals pressed a Rhode Island federal judge last week to split Loestrin buyers' fraud and antitrust claims into two separate trials, arguing that a jury would be confused if all of the allegations were thrown at them in one proceeding. 

  10. July 17, 2019

    Loestrin Buyers Win Cert. In Antitrust Battle With Pharmas

    A Rhode Island federal judge agreed to certify a class of Loestrin purchasers suing Warner Chilcott and Watson Pharmaceuticals for nearly $2 billion for allegedly sidelining generic alternatives to the widely used birth control drug.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!